Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 3, 2004, Pages 188-197

  Maurea, Simone ^a,c   Caraco C ^b   Klain, M ^a   Mainolfi, C ^a   Salvatore, M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Institute of Biomolecular chemistry   (Italy)

^c NONE   (Italy)

Author keywords

Adrenal glands; Magnetic resonance imaging; Neoplasms; Radiopharmaceutics

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CHOLESTEROL DERIVATIVE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; IODINE 131;

ADRENAL BIOPSY; ADRENAL CANCER; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL CYST; ADRENAL METASTASIS; ADRENAL SCINTISCANNING; ADRENAL TUMOR; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MYELOLIPOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SIGNAL NOISE RATIO; TREATMENT PLANNING;

19-IODOCHOLESTEROL; 3-IODOBENZYLGUANIDINE; ADENOMA; ADRENAL GLAND NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 8444225365     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 1995;16:460-84.
2. Gross MD, Shapiro B. Clinical review 50. Clinical silent adrenal masses. J Clin Endocrinol Metab 1993;77:885-8.
3. Ross MS, Aron DC. Hormonal evaluation of the patient with an incidentally discovered adrenal mass. N Engl J Med 1990;323:1402-5.
4. Mayo-Smith WW, Boland GW, Noto RB, Lee M. State-of-the-art adrenal imaging. Radiographics 2001;21:995-1012.
5. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnik NR, Londy F. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. Am J Roentgenol 1998;170:747-52.
6. Heinz-Peer G, Honigschnabl S, Schneider B, Niederle B, Kaserer K, Lechner G. Characterization of adrenal masses using MR imaging with histopathologic correlation. Am J Roentgenol 1999;173: 15-22,
7. Francis IR, Gross MD, Shapiro B, Korobkin M, Quint LE. Integrated imaging of adrenal disease. Radiology 1992;184:1-13.
8. Falke THM, Sandler MP. Classification of silent adrenal masses: time to get practical. J Nucl Med 1994;35:1152-4.
9. Lawson MA. Role of molecular imaging in management of nonhypersecreting adrenal masses. J Nucl Med 2001;42:893-4.
10. Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M. The diagnostic role of radionuclide imaging in the evaluation of patients with non-hypersecreting adrenal masses. J Nucl Med 2001;42: 884-92.
11. Truong B, Jolles PR, Mullaney JM. Primary adrenal lymphoma: gallium scintigraphy and correlative imaging. J Nucl Med 1997;38:1770-1.
12. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 1992;33: 1125-31.
13. Boland GW, Goldberg MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MM et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;194:131-4.
14. 18F fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168:1357-60.
15. Maurea S, Mainolfi C, Bazzicalupo L, Panico MR, Imparato C, Alfano B et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol 1999; 173:25-9.
16. Bergstrom M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerstrom G et al. PET imaging of adrenal cortical tumors with the 11betahydroxylase tracer C-11 metomidate. J Nucl Med 2000;41:275-82.
17. Maurea S, Lastoria S, Caraco C, Klain M, Varrella P, Acampa W et al. The role of radiolabeled somatostatin analogs in adrenal imaging. Nucl Med Biol 1996;23:677-80.
18. Slapa RZ, Jakubowski W, Januszewicz A, Kasperlik-Zaluska AA, Dabrovska E, Fijuth J et al. Discriminatory power of MRI for differentiation of adrenal non-adenomas vs adenomas evaluated by means of ROC analysis: can biopsy be obviated? Eur Radiol 2000;10:95-104.
19. Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002;222:629-33.
20. Maurea S, Lastoria S, Cuocolo A, Celentano L, Salvatore M. The diagnosis of non-functioning pheochromocytoma: the role of I-123 metaiodobenzylguanidine imaging. Clin Nucl Med 1995;20:22-4.
21. Barzon L, Scaroni C, Sonino N, Fallo F, Gregianin M, Macri C et al. Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. J Clin Endocrinol Metab 1998;83:55-62.
22. Maurea S, Caracò C, Castelli L, Filice S, Alfano B, Ruffolo F et al. La risonanza magnetica nello studio delle neoplasie surrenaliche: analisi qualitativa e quantitativa dell'intensità di segnale. Radiol Med 1998;95:199-207.
23. Maurea S, Klain M, Caracò C, Ziviello M, Salvatore M. Diagnostic accuracy of radionuclide imaging using iodine-131 nor-cholesterol or MIBG in patients with hypersecreting or non-hypersecreting adrenal tumors. Nucl Med Comm 2002;23:951-60.
24. Young WF. Management approaches to adrenal incidentalomas: a view from Rochester, Minnesota. Endocrinol Metab Clin North Am 2000;29:159-85.
25. Schteingart DE. Management approaches to adrenal incidentalomas: a view from Ann Arbor, Michigan. Endocrinol Metab Clin North Am 2000;29:127-39.